W.H.O. Announces Resumption of Hydroxychloroquine Testing for Covid-19

After a 10-day suspension, hydroxychloroquine trials will be resumed with 3,500 patients in 35 countries, the Director General said.

RIO DE JANEIRO, BRAZIL - After analyzing a study published by the medical-scientific journal The Lancet, Tedros Ghebreyesus Adhanom, the World Health Organization's (WHO) Director General, announced yesterday, June 3rd, during a press conference that the group in charge of clinical trials of substances capable of fighting the novel coronavirus will resume its testing protocols with chloroquine and its latest variant, hydroxychloroquine.

"As you know, last week the Executive Solidarity Testing Group [name given to the research group seeking effective drugs against SARS-CoV-2] Subscribe to our Premium Membership Plan. Already Subscribed?